Tevogen Bio received notice from Nasdaq on April 16, 2026, regarding failure to meet the $50 million minimum market value of listed securities (MVLS) requirement. On April 17, 2026, the company received a second notice regarding failure to meet the $15 million minimum market value of publicly held shares (MVPHS) requirement. The company has 180 calendar days, until October 13 and October 14, 2026, respectively, to regain compliance. The notifications have no immediate impact on the company's current listing or trading status on the Nasdaq Global Market.